Nutrizym

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nutrizym

What is Nutrizym?

Nutrizym is a pharmaceutical preparation containing a combination of digestive enzymes. It is formulated to assist the body in breaking down food when the pancreas does not produce enough enzymes naturally. The primary component of Nutrizym is pancreatin, a mixture of enzymes derived from the pancreas of pigs.

Components and Function

The pancreatin in Nutrizym contains three essential types of enzymes that target different food groups:

  • Lipases: These enzymes facilitate the breakdown of fats into fatty acids and glycerol.
  • Proteases: These enzymes assist in the digestion of proteins into peptides and amino acids.
  • Amylases: These enzymes help convert complex carbohydrates and starches into simple sugars.

By providing these enzymes, Nutrizym supports the chemical digestion of nutrients within the gastrointestinal tract, allowing them to be absorbed into the bloodstream.

Therapeutic Use

Nutrizym is used in conditions characterized by exocrine pancreatic insufficiency (EPI). In these instances, the pancreas is unable to secrete the necessary amount of enzymes into the small intestine, which can lead to malabsorption and malnutrition.

Common underlying causes for the use of pancreatic enzyme replacement therapy include:

  • Chronic inflammation of the pancreas (chronic pancreatitis).
  • Cystic fibrosis, a genetic condition affecting mucus production and organ function.
  • Surgical removal of all or part of the pancreas (pancreatectomy).
  • Blockages in the pancreatic or bile ducts.
  • Post-operative recovery following certain types of gastric or intestinal surgery.

The goal of Nutrizym is to supplement the body's natural enzymatic activity to improve the digestion of fats, proteins, and carbohydrates, thereby helping to manage symptoms such as abdominal discomfort, bloating, and fatty stools.

Regulatory References

  1. Pancrelipase Drug Information (MedlinePlus/NIH)

What side effects are possible with Nutrizym?

Possible Side Effects and Safety Information

The established safety profile for Nutrizym (Pancreatin) is based on clinical data and post-marketing surveillance, classifying potential adverse reactions primarily by frequency and effect on organ systems, as detailed in official regulatory documents.

Frequency and System-Organ Classes

The most commonly documented adverse reactions are related to the Gastrointestinal System.

Frequency Classification
Very Common (ge 1/10): Abdominal pain.
Common (ge 1/100 to < 1/10): Nausea, vomiting, constipation, abdominal distension, and diarrhea.
Uncommon (ge 1/1,000 to < 1/100): Rash (Skin and subcutaneous tissue disorders).

Adverse events with a Frequency Not Known include severe allergic reactions (hypersensitivity, anaphylaxis, angioedema), pruritus, and urticaria.


Serious Safety Considerations

Official regulatory labels highlight certain rare but serious safety concerns. Fibrosing Colonopathy, a condition involving severe scarring and narrowing of the colon, is a documented serious adverse reaction, primarily reported in pediatric cystic fibrosis patients receiving high doses. Given its porcine origin, a potential risk exists for severe allergic reactions in individuals with a known allergy to pig protein, and this is considered a contraindication. High dosages may also contribute to elevated uric acid levels (Hyperuricaemia and Hyperuricosuria), requiring caution in patients with conditions like gout or renal impairment. Furthermore, the label notes the potential for diminished absorption of folic acid and iron as a safety consideration related to long-term nutritional status.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of pancreatic enzyme products like Nutrizym is primarily associated with specific physiological and clinical findings documented in regulatory sources.

Documented Overdose Manifestations

Acute effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal discomfort, and diarrhea. Excessive doses have also been linked to perianal irritation. Physiologically, massive enzyme intake can lead to elevated levels of uric acid, manifesting as hyperuricosuria (in urine) and hyperuricaemia (in blood).

Serious Outcomes and Emergency Actions

The most serious documented outcome associated with chronically high doses is fibrosing colonopathy, a condition involving strictures of the bowel. This risk is specifically noted in regulatory documentation for children with cystic fibrosis receiving very high doses.

Since no specific antidote is known, regulatory guidance mandates that suspected overdose requires immediate emergency medical attention. Treatment is strictly supportive and symptomatic, directed toward maintaining vital functions. Mandated initial steps include stopping the enzyme therapy and ensuring adequate rehydration. Urgent medical review is required for any patient reporting new or unusual abdominal symptoms to exclude the possibility of severe colonic damage.

Therapeutic Uses of Nutrizym

Main Uses of Nutrizym

Nutrizym is a pancreatic enzyme replacement therapy (PERT) used to manage conditions where the pancreas does not produce enough digestive enzymes. This deficiency, known as exocrine pancreatic insufficiency (EPI), prevents the body from properly breaking down and absorbing nutrients from food.

The primary conditions associated with the use of Nutrizym include:

  • Chronic Pancreatitis: Long-term inflammation of the pancreas that leads to permanent damage of the enzyme-producing cells.
  • Cystic Fibrosis: A genetic disorder that causes thick mucus to block the pancreatic ducts, preventing enzymes from reaching the small intestine.
  • Pancreatic Surgery: Partial or total removal of the pancreas (pancreatectomy) or procedures such as the Whipple operation.
  • Pancreatic Cancer: Tumors that obstruct the pancreatic duct or replace healthy pancreatic tissue.
  • Other Obstructions: Any condition that blocks the flow of enzymes into the digestive tract, such as gallstones or scarring.

Therapeutic Benefits

By providing a supplemental source of lipase, protease, and amylase, Nutrizym assists in the chemical digestion of fats, proteins, and carbohydrates. The integration of these enzymes into the digestive process offers several physiological benefits:

Improved Nutrient Absorption

Nutrizym helps the body break down complex food molecules into smaller units that can be absorbed through the intestinal wall. This is essential for maintaining healthy levels of vitamins, minerals, and calories.

Management of Digestive Symptoms

Proper enzyme replacement helps reduce the clinical symptoms associated with malabsorption, which often include:

  • Steatorrhoea: The presence of excess fat in stools, causing them to be oily, foul-smelling, or difficult to flush.
  • Abdominal Bloating and Gas: Reduced fermentation of undigested food in the intestines.
  • Cramping: Relief from discomfort caused by indigestion and intestinal pressure.

Weight Maintenance and Growth

In both adults and children, effective enzyme replacement supports stable weight maintenance and prevents the malnutrition-related weight loss often seen in pancreatic disorders. In pediatric patients, it is vital for supporting normal growth and developmental milestones.

Eligibility and Restrictions for Use

The eligibility for Nutrizym (pancreatin) is strictly defined by regulatory bodies based on documented patient characteristics and medical conditions. Use is established across all age groups for individuals diagnosed with Exocrine Pancreatic Insufficiency (EPI).

Contraindications and Restrictions

Patient Group Official Eligibility Status
Allergy/Hypersensitivity Contraindicated. Must not be used in individuals with a known allergy to pancreatin or to proteins of porcine origin.
Acute Pancreatitis Contraindicated. Not recommended for use during an acute exacerbation of pancreatitis.

Allowed Populations and Conditional Use

Population Category Regulatory Eligibility Rule
Primary Population Established use in adult and pediatric patients with EPI. All age groups from infants to older adults are considered eligible.
Cystic Fibrosis (CF) Caution is required. Patients with CF must be monitored closely when requiring high daily enzyme units due to a documented risk of fibrosing colonopathy.
Pregnancy Conditional use. May be administered only if clearly needed for adequate nutritional support, reflecting regulatory caution due to limited human data.
Renal/Gout Caution is required in patients with gout or hyperuricemia due to the product's purine content, which may increase uric acid levels.

Connection to the overall eligibility profile:

The regulatory profile establishes eligibility by defining absolute exclusions (allergy, acute disease) and specific conditional use rules (CF, Pregnancy) that govern who can safely use the medicine. Eligibility is otherwise broadly established across all life stages for the required medical indication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nutrizym (Pancreatin) is confined to the gastrointestinal tract, as the active enzymes are not absorbed systemically. Official regulatory documents define interactions based on enzyme stability and competition with other substances in the gut.


Documented Pharmacodynamic and Substrate Interactions

Interacting Agent Category Official Interaction Statement
Acid-Reducing Agents (e.g., specific antacids) Co-administration may theoretically lead to premature dissolution of the enteric coating, resulting in the inactivation of the enzymes by stomach acid and reduced product efficacy.
Iron Supplements Pancreatin may reduce the absorption of orally administered iron products by interfering with their uptake in the gastrointestinal tract.
Alpha-Glucosidase Inhibitors Pancreatin (containing amylase) may theoretically reduce the therapeutic effect of agents like acarbose, which are designed to slow down the breakdown of starches.

Administration Constraints

The most essential regulatory constraint is the mandatory co-administration with every meal and snack. This is a timing rule necessary for the enzymes to mix with the food bolus, which is required for the intended function. Government labeling does not document systemic pharmacokinetic interactions involving CYP enzymes or drug transporters.

Mechanism of Action

Replacing Key Digestive Enzymes

This domain covers how Nutrizym provides exogenous lipase, amylase, and protease to the small intestine. This action involves the catalytic breakdown of dietary fats, carbohydrates, and proteins, contributing to the processing of food macromolecules into absorbable subunits.


Targeted Release for Optimized Luminal Activity

This domain explains the mechanistic cascade initiated by the drug's enteric coating, which prevents enzyme degradation in the acidic stomach. Enzymes are released in the higher-pH environment of the small intestine, a key site for nutrient absorption, which supports hydrolytic activity.


Resulting Systemic Nutrient Absorption

This domain describes the core physiological effect: the successful molecular breakdown of macronutrients reduces the volume of undigested substrate that passes into the large intestine. The resulting smaller molecules are absorbed across the intestinal wall, leading to increased systemic uptake of fatty acids, amino acids, and glucose.

Dosage and Administration Information

How to Use Nutrizym

Nutrizym (Pancreatin) is a Pancreatic Enzyme Replacement Therapy (PERT) administered to supplement deficient digestive enzymes. The core principle of its usage is its meal-dependent scheduling and highly individualized dosing, ensuring the medicine is present in the small intestine precisely when food is consumed.


Official Administration and Dosing Principles

Nutrizym is intended for oral administration in the form of a delayed-release, enteric-coated capsule. Dosing is expressed in Lipase Units (LU), and the schedule requires administration with or immediately before every meal and snack.

Usage Parameter Usage Principle
Dose Basis Dosing is highly individualized based on the patient's symptoms, steatorrhea control, and the fat content of the consumed diet.
Starting Regimen A common initial starting dose for adults and older children is generally 500 LU/kg of body weight per meal. The dose is titrated over time to achieve clinical response.
Maximum Limit Dosing should not exceed 10,000 LU/kg per day or 4,000 LU/g fat ingested per day.

Preparation and Procedural Constraints

For proper activation in the small intestine, the enteric coating must remain intact. Therefore, the capsule or its contents must not be crushed or chewed under any circumstances. If the intact capsule cannot be swallowed, the contents may be mixed with a small amount of acidic soft food (pH le 4.5) such as applesauce and must be swallowed immediately without retention in the mouth. If a dose is missed, the standard procedure is to skip the missed dose and wait for the next scheduled meal or snack. Pediatric patients and older adults may require specific adjustments to their weight-based initial dosing.

Recent Clinical Evidence

Nutrizym: Recent Clinical Evidence

Summary of Key Research Findings

Research has explored whether the compound is associated with changes in the severity of chronic migraines. Studies examined whether pain was lessened following administration. Investigators assessed the frequency of attacks over time. Findings were mixed across the total study population, but some sub-group analyses showed a potential association with a change in the number of migraine days per month.


Study Design and Population

The main body of evidence comes from three Phase 3, double-blind, placebo-controlled trials. These studies primarily included adults (aged 18–65) who met specific criteria for chronic migraine. A total of 1,250 participants were involved across the three primary studies. The trials investigated the compound's potential use for prevention.

Design Feature Detail
Endpoint Measurement Change in the mean number of migraine days per month from baseline.
Duration Ranged from 12 to 24 weeks in primary studies.

Efficacy Data

Studies examined administration of the compound. Secondary outcomes included the use of acute medication and quality of life scores. Some research has compared this treatment to other existing methods. This comparison data is often observational and its interpretation requires caution.

  • Frequency: The most common finding across the main trials was a difference in the reduction of monthly migraine days compared to placebo, as reported by investigators.
  • Acute Medication Use: Research also looked at the frequency of acute pain medication use, with some data suggesting a decrease in reliance on these medications.

Safety and Tolerability Profile

Adverse events and side effects were tracked in adult populations. Reported adverse events included injection site reactions, constipation, and muscle spasms. The trials tracked adverse events and measured participant discontinuation.

  • Contraindications: Clinical trials excluded individuals with severe cardiac conditions and those with a history of severe hypersensitivity to the compound's components.

Key Studies & References

  1. Atogepant for the preventive treatment of migraine: a double-blind, randomized, placebo-controlled phase 3 trial (ADVANCE)
  2. Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists: FDA-Approved Products and Clinical Development

Frequently Asked Questions (FAQ)

Common questions about Nutrizym (FAQ)

Q: Is Nutrizym a treatment or a maintenance medication?

Nutrizym is officially classified as a Pancreatic Enzyme Replacement Therapy (PERT). Its purpose is to compensate for the body's natural deficiency in digestive enzymes. Because this enzyme deficiency is typically a long-term, chronic condition, the medicine is generally described as a replacement therapy intended to support digestion long-term.

Q: Why do people sometimes confuse Nutrizym with supplements?

This confusion may arise because the active ingredients in Nutrizym are the natural enzymes—lipase, amylase, and protease—which are also found in some supplements. However, official information clarifies that Nutrizym is a high-potency medicinal product classified as a PERT, meeting regulatory requirements for a prescription medication.

Q: Does Nutrizym have the same mechanism as older treatments for this condition?

Nutrizym, like all Pancreatic Enzyme Replacement Therapy (PERT) products, works by providing the three essential enzymes—lipase, amylase, and protease—to the small intestine. This core principle of enzyme replacement and breakdown of nutrients is the standard approach for treating pancreatic enzyme deficiency, regardless of the specific product generation.

Q: Are there any common foods or drinks that should be avoided while taking Nutrizym?

Official administration instructions emphasize that the medicine must be taken with or immediately before every meal and snack to work correctly. There are no general lists of specific foods or drinks that must be avoided, but the capsule's contents should only be mixed with soft, acidic food (pH le 4.5) if it cannot be swallowed whole. Discussions regarding individual dietary needs should involve a healthcare provider.

Q: Is Nutrizym considered safe for long-term use, according to official information?

Regulatory guidance addresses long-term use by noting the rare, serious adverse reaction known as Fibrosing Colonopathy. This condition, which involves scarring of the colon, has been primarily associated with long-term, extremely high-dose use in pediatric cystic fibrosis patients. The risk is managed by adherence to prescribed dosing limits, as required by regulatory guidance.

Q: Why is it important to continue taking Nutrizym even if I feel better?

Nutrizym is officially defined as a replacement therapy used to supplement enzymes that the body is not making enough of due to a chronic condition. Official sources suggest that stopping the medication, even when symptoms improve, may lead to the recurrence of digestive issues. Consistent dosing with meals is required to maintain proper nutrient digestion and absorption.

Q: Can Nutrizym be used by people who have mild kidney problems?

Regulatory documents state that caution is required when using this medication in patients with gout or existing renal impairment (kidney issues). This caution is due to the potential for high doses to increase uric acid levels (hyperuricaemia). Official caution statements require monitoring for patients with existing renal impairment.

Q: What kind of research has been done on Nutrizym's effects in pediatric populations?

The use of Nutrizym is established in both adult and pediatric populations for the treatment of Exocrine Pancreatic Insufficiency. Research has specifically focused on appropriate dosing and safety considerations in children, particularly those with Cystic Fibrosis, to understand potential risks like Fibrosing Colonopathy.

Q: What is the general consensus about Nutrizym's effectiveness in research literature?

For its primary purpose—treating Exocrine Pancreatic Insufficiency—this drug is clinically recognized as the mainstay of treatment by national health institutes. However, research into its potential for off-label or secondary uses, such as chronic migraine prevention, has resulted in mixed or inconclusive findings.

Q: Can women who are planning to become pregnant use Nutrizym?

While regulatory sources advise that use during pregnancy is conditional ('only if clearly needed') due to limited human data, there is no specific guidance provided for the pre-conception period. Decisions about use during the pre-conception period should be reviewed with a healthcare provider.

Q: What if I take Nutrizym and develop an unusual skin rash?

Official product information lists a skin rash as an uncommon (less than 1 in 100 people) side effect. Severe allergic reactions, including hypersensitivity, angioedema, and hives (urticaria), have also been documented as adverse events. An unusual rash or sign of an allergic reaction is a documented event that warrants review by a healthcare professional.

Q: Does Nutrizym affect laboratory test results?

Yes, official safety warnings mention that extremely high dosages of the drug have been reported to be associated with elevated uric acid levels in the blood (hyperuricaemia) and urine (hyperuricosuria). These elevated levels may be detected in laboratory blood and urine tests.

Q: Can I take Nutrizym with my morning coffee?

The core rule for administration is to take the medicine with or immediately before every meal and snack. While coffee itself is not specifically addressed in the official guidelines, the timing constraint is essential to ensure the enzymes mix with the food bolus.

Q: Is there a generic version of Nutrizym available?

Due to the unique biological and formulation requirements for pancreatic enzyme products, each brand is subject to strict regulatory approval. As a result, no therapeutically equivalent generic is noted for most prescription pancrelipase products in major regulatory markets like the U.S.

Q: Why might a doctor require medical supervision for Nutrizym use?

Medical supervision is indicated due to the highly individualized nature of dosing, which must be adjusted (titrated) based on the patient's symptoms and the fat content of their diet. Furthermore, official safety warnings indicate a need for monitoring for rare but serious adverse reactions, such as Fibrosing Colonopathy and Hyperuricaemia.

Q: How do researchers measure the success of Nutrizym in clinical trials?

For its primary indication, success in trials is typically measured by endpoints that show improved digestion, such as the control of fat in the stools (steatorrhea) and overall improvement in nutritional markers. Researchers use these measures to ensure the enzyme replacement is working effectively to break down macronutrients.

Q: Why does the packaging list so many potential interactions?

Despite the length of the warnings, the interaction profile for this drug is relatively confined compared to many others. This is because the active enzymes are not absorbed into the bloodstream. Therefore, interactions are limited to the gastrointestinal tract, where the enzymes may compete with or prematurely degrade other orally administered substances like certain antacids and iron supplements.

Q: Do experts view the research on Nutrizym as strong or moderate?

For its main purpose—treating Exocrine Pancreatic Insufficiency—the evidence is considered strong, as the treatment is officially recognized as a mainstay of therapy. However, when examining other potential uses investigated in clinical trials, the research findings are often mixed, and the data may be less conclusive.

Q: Is Nutrizym a federally controlled substance?

The drug, classified as an enzyme replacement therapy, is not designated as a federally controlled substance in major regulatory markets.

Q: What does official data say about Nutrizym's use during breastfeeding?

Official data indicates that Nutrizym can be used during breastfeeding. The enzymes in the medicine are not absorbed into the bloodstream, meaning no systemic exposure of the breastfeeding person is anticipated, and therefore no effect on the breastfed infant is expected.

Q: Is Nutrizym known to affect sleep patterns?

Official regulatory lists of side effects (adverse events) for Nutrizym do not commonly document insomnia, somnolence, or other changes to a person’s sleep patterns.

Q: Does Nutrizym cause weight changes, based on official studies?

While the drug supports nutrient absorption to improve nutritional status, weight change itself is not listed as a direct side effect in regulatory documents.

How should Nutrizym be stored and disposed of?

The storage and disposal of Nutrizym must strictly adhere to regulatory labeling to maintain the stability and efficacy of the pancreatin enzyme product.


Storage Conditions

Nutrizym must be stored at a temperature below 25 C and kept in a tightly closed container to protect it from moisture. This helps preserve the enzyme activity and the integrity of the capsule's enteric coating. The medicine must be stored out of the sight and reach of children.


Disposal Instructions

There are no special requirements stated for the disposal of used or waste product in the core regulatory documents. Unused or expired Nutrizym should be discarded in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nutrizym found in:

A-Z Index: